Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-004407-40 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This will be an open label study to assess the influence of renal impairment on the pharmacokinetics (PK) of GLPG0634 and its metabolite after once daily oral administrations of 100 mg GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls.
Also, safety and tolerability of once daily oral doses of GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls will be evaluated.
The study will be divided in two parts.
In Part 1, 3 subjects with severe renal impairment or end-stage renal disease (ESRD) not yet requiring dialysis (Group 1) will be recruited first. Thereafter, 3 subjects with normal renal function (Group 2) will be recruited. If a substantial effect on the PK in renal impaired subjects is observed on Day 10, the sponsor may elect to stop Part 1 of the study without enrolling the complete set of subjects and Part 2 will be initiated. In case no substantial effect on the PK is observed, 3 further subjects in both Group 1 and 2 will be recruited and analysed. If a substantial effect on the PK is observed, the study will proceed to Part 2. Part 2 of the study will not be conducted, if in Part 1 no substantial difference in PK is seen.
In Part 2, Group 3 (mild renal impairment) and Group 4 (moderate renal impairment) will be recruited first. After completion of the mild and moderate impairment groups, Group 5 (normal renal function) will be recruited.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1 - Severe renal impairment | Experimental | Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days |
|
| Part 1: Normal renal function | Experimental | Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days |
|
| Part 2 - Mild renal impairment | Experimental | Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days |
|
| Part 2 - Moderate renal impairment | Experimental | Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days |
|
| Part 2 - Normal renal function | Experimental | Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GLPG0634 | Drug | 100 mg oral tablet, intake once daily for 10 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed plasma concentration (Cmax) | Cmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Area under the plasma drug concentration-time curve over 24 hours (AUC0-24h) | AUC0-24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative amount excreted in urine expressed in μg and % of the dose administered (Ae) | Ae of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12) |
| Renal clearance (CLR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pille Harrison, MD | Lakefront Biotherapeutics NV | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CRS Clinical Research Services Kiel GmbH | Kiel | Germany |
Not provided
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| C584571 | GLPG0634 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
CLR (calculated as Ae/AUC, where Ae and AUC are calculated over the same interval) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function |
| Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12) |
| Plasma concentration observed at 24 h post-dose (C24h) | C24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Average plasma concentration (Cavg) | Cavg (calculated as AUC0-24h/24h) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Time of occurrence of Cmax (tmax) | Tmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Area under the plasma drug concentration-time curve from zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-z) | AUC0-z of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Area under the plasma drug concentration-time curve, extrapolated to infinity (AUC0-∞) | AUC0-∞ of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Apparent terminal half-life (t1/2,λz) | t1/2,λz (calculated from (ln 2)/λz being the apparent terminal rate constant) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Metabolite over parent ratio of AUC0-24h (R) | R (metabolite over parent ratio of AUC0-24h) after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| Accumulation ratio (Rac) | Rac (calculated as AUC0-24h Day 10/AUC0-24h Day 1) after dosing in subjects with renal impairment versus subjects with normal renal function | Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17) |
| The number of subjects with adverse events | To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of adverse events (AEs) | From screening up to 10 days after last dose (Day 20) |
| The number of subjects with abnormal laboratory parameters | To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal laboratory parameters | From screening up to 10 days after last dose (Day 20) |
| The number of subjects with abnormal vital signs | To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal vital signs | From screening up to 10 days after last dose (Day 20) |
| The number of subjects with abnormal electrocardiogram (ECG) | To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal electrocardiogram (ECG) | From screening up to 10 days after last dose (Day 20) |
| The number of subjects with abnormal physical examination | To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal physical examination | From screening up to 10 days after last dose (Day 20) |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |